AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...
A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days of vaccination ...
US health officials have issued a warning linking RSV vaccines to an increased risk of a serious neurological condition. The ...
Professor of Paediatrics and vaccinologist, Royal Childrens Hospital, University of Melbourne and Murdoch Childrens Research Institute (MCRI); Associate Dean International, University of Melbourne ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
While still recommending the jabs for eligible adults, the FDA officials said Guillain-Barré syndrome would now be listed as a risk in leaflets ... vaccine reaction data on two RSV jabs, called ...
Despite more than 50 years of research, there are no RSV vaccines approved or in Phase III clinical trials. Key challenges include peak disease in infants less than 3 months of age and ...
Pregnant women across Australia will be offered a free vaccine to protect their babies against respiratory syncytial virus (RSV) from next month. The government's $174.5 million investment will ...